Bentzen A J, Vejlsgaard R, Jacobsen J, Tybring L
Infection. 1975;3(3):154-60. doi: 10.1007/BF01641339.
Pivmecillinam, a new penicillin-like antibiotic, is a member of the amidinopenicillanic acid group. Its mode of action differs from that of the classical penicillins and it exhibits no cross-resistance with them. Fifty-two gerontopsychiatric patients, median age 81 years, with E. coli, Klebsiella, and Proteus bacteriurias were divided into three comparable groups. In a ten week open clinical trial the patients were treated with pivmecillinam, pivampicillin or the two drugs given alternately in doses reduced in stages. The bacteriuria in all groups cleared almost completely in three days. Pivmecillinam compared favourably with pivampicillin especially at the end of the reduced medication. The alternating treatment seemed to be superior to treatment with either drug administered separately. No development of resistance was observed. No toxic effect on the liver, kidney, or bone marrow was seen in any of the three groups. In the group receiving pivmecillinam alone, no ampicillin-like skin rashes occurred.
匹美西林是一种新型青霉素类抗生素，属于脒基青霉素酸类。其作用方式不同于传统青霉素，且与传统青霉素无交叉耐药性。52名老年精神病患者，中位年龄81岁，患有大肠杆菌、克雷伯菌和变形杆菌菌尿症，被分为三个可比组。在一项为期十周的开放临床试验中，患者分别接受匹美西林、匹氨西林治疗，或两种药物交替使用且剂量逐步减少。所有组的菌尿症在三天内几乎完全清除。匹美西林与匹氨西林相比效果良好，尤其是在减少用药末期。交替治疗似乎优于单独使用任何一种药物的治疗。未观察到耐药性的产生。三组中均未发现对肝脏、肾脏或骨髓的毒性作用。在单独接受匹美西林治疗的组中，未出现类似氨苄西林的皮疹。
